We have read with some concerns the narrative review recently published by Eden et al 1 addressing important questions in the field of oncofertility, including the gonadotoxicity of anticancer ...
Mounting data suggest that lower doses of anti-PD(L)1 agents can be as efficacious as label-approved doses at a fraction of its cost. We compare the outcomes of patients treated with low-dose (LD) and ...
In our original review, 1 we document the weak evidence base to support fertility preservation for patients with cancers and cancer survivors. Although the decision to pursue these interventions ...
Development of a Composite Score Based on Carbohydrate Antigen 19-9 Dynamics to Predict Survival in Carbohydrate Antigen 19-9–Producing Patients With Pancreatic Ductal Adenocarcinoma After Neoadjuvant ...
A retrospective study was performed to analyze the results of clinical germline genetic testing (March 2020-January 2023) among a cohort of consecutive Emirati patients at risk for hereditary breast ...
Electronic patient-reported outcome (ePRO) tools are increasingly used to provide first-hand information on patient's symptoms and quality of life. This study explored how patients and health care ...
Changes in the Epidemiologic Pattern of Primary CNS Tumors in Response to the Aging Population: An Updated Nationwide Cancer Registry Data in the Republic of Korea Telemedicine is widely used for ...
Erratum: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial The results of the interim ...
Economic Evaluation of Targeted Therapies for Anaplastic Lymphoma Kinase– and ROS1 Fusion–Positive Non–Small Cell Lung Cancer in India We selected 250 consecutive participants from the SECOC ...
Latin American Consensus for the Evaluation and Treatment of Patients With Metastatic/Locally Advanced Urothelial Carcinoma This is a quality assurance research using nonexperimental design and did ...
Validity and Efficiency of Progression-Free Survival-2 as a Surrogate End Point for Overall Survival in Advanced Cancer Randomized Trials Patient 1 had rapidly progressive ECD involving the CNS. A ...